Inovio =C2=BB Investor Relations =C2=BB = News Release

Inovio Biomedical Corporation=20

About=20 Us
- Overview
- Leadership
- Partnerships
- Careers
- Conta= ct=20 Us
Products

Pipeline

Cancer=20 DNA Vaccines

= Infectious=20 DNA Vaccines

Anti-In= flammatory=20 Drugs

Animal=20 Health Products

Te= chnology

Te= chnology=20 Overview

DNA = Vaccines

Electroporation-Based=20 DNA Delivery

DNA= =20 Plasmid Manufacturing

Intellectual=20 Property

Scientific=20 Publications

Gene=20 Regulation Technology

Clin= ical=20 Trials

Canc= er=20 Trials

Infectious=20 Disease Trials

News

News=20 Releases

Events/Presentations
Industry=20 News/Research

Press=20 Kit

Investor=20 Relations

Corporate=20 Governance

Stock=20 Quote

S= EC=20 Filings

Analyst=20 Coverage

Information=20 Request

I= nvestor=20 FAQ

Investor=20 Relations Home
= News=20 Releases
Corporate=20 Governance
Stock=20 Quote
S= EC=20 Filings
Analyst=20 Coverage
Information=20 Request
I= nvestor=20 FAQs
Conta= cts

home =C2=BB investor=20 relations =C2=BB News Release

News Release

View printer-friendly version

<< Back

Inovio Biomedical H1N1 = Influenza DNA=20 Vaccines Demonstrate 100% Responses Against Swine Flu in = Vaccinated=20 Pigs

Preclinical Data Validates Capability of Inovio = SynConTM DNA=20 Vaccines to Provide Universal Protection Against Unmatched Flu = Virus=20 Strains
SAN=20 DIEGO--(BUSINESS WIRE)--Jul. 13, 2009-- Inovio Biomedical Corporation (NYSE = Amex:INO), a=20 leader in DNA vaccine design, development and delivery, announced = today=20 that the company's SynCon=E2=84=A2 H1N1 influenza DNA vaccines = achieved protective=20 antibody responses against H1N1 swine influenza virus = (A/Swine/Iowa/35233/1999) in 100% of=20 pigs immunized with a two-dose vaccine regimen.

Dr. Niranjan Sardesai, Senior VP, Research = &=20 Development, presented the data at the Annual Conference of = DNA=20 Vaccines in Asia=20 2009 held in Beijing, China, July = 9-10,=20 2009, in a presentation entitled, =E2=80=9CPandemic and = Seasonal Influenza=20 DNA Vaccines Delivered Via Electroporation.=E2=80=9D

In this study, scientists immunized pigs with consensus H1N1 = influenza=20 DNA vaccine candidates on day 0, day 14, and day 28. Sera = collected on day=20 28 and day 42, after two or three doses of vaccine, respectively, = showed=20 hemagglutination inhibition (HI) titers above the protection = threshold in=20 100% of the vaccinated animals against a swine H1N1 virus = previously=20 isolated from pigs. On-going additional animal studies are testing = the=20 ability of Inovio=E2=80=99s SynCon=E2=84=A2 human H1N1 and swine = H1N1 based vaccines to=20 cross-protect from currently circulating human and swine H1N1 = viruses as=20 well as the new influenza A/H1N1 of swine origin.

In a similar collaborative study with scientists from the = National=20 Microbiology Laboratory of the Public Health Agency of Canada and the = University=20 of Pennsylvania, Inovio previously demonstrated that mice = immunized=20 with Inovio=E2=80=99s SynCon=E2=84=A2 H1N1 DNA vaccine provided = 100% protection in a=20 lethal challenge study against an unmatched H1N1 virus that caused = the=20 1918 Spanish flu, which killed over 40 million people worldwide. =

Dr. J. Joseph Kim, Inovio=E2=80=99s CEO, said, = =E2=80=9COur innovative=20 SynCon=E2=84=A2 technology has the potential to protect people = from influenza=20 strains not exactly like the ones that make up the existing = vaccines. This=20 is a clear advantage for our universal flu program over = conventional=20 influenza vaccines. We are pleased to report our H1N1 preclinical = results=20 using pigs, a more natural model for the current influenza = pandemic. We=20 look forward to advancing our SynCon=E2=84=A2 universal flu = vaccine program toward=20 clinical investigation.=E2=80=9D

Inovio=E2=80=99s novel SynCon=E2=84=A2 technology enables the = company to design=20 DNA-based vaccines with the potential to protect against unmatched = sub-types and strains of pathogens. Inovio has created = SynCon=E2=84=A2 DNA=20 vaccines based on influenza HA, NA, and NP proteins = that are=20 common to strains H1N1, H2N2, H3N2, and H5N1, which make up the = majority=20 of seasonal and pandemic influenza. Using a designer approach, = Inovio can=20 formulate these DNA plasmids together to rapidly develop a = universal=20 influenza vaccine potentially targeting all these strains. The = resulting=20 vaccine could target seasonal as well as pandemic-potential = influenza=20 strains such as avian influenza and swine flu, which has already = been=20 designated pandemic status. Significantly, being based on a common = set of=20 antigens derived from a broad range of flu strains, such a = universal=20 vaccine would have the potential to provide greater protection = against=20 evolving, unmatched flu strains.

About Inovio = Biomedical=20 Corporation

Inovio = Biomedical is=20 engaged in the design, development, and delivery of a new = generation of=20 vaccines, called DNA vaccines, focused on cancers and infectious = diseases.=20 The company=E2=80=99s SynCon=E2=84=A2 technology enables the = design of DNA-based vaccines=20 capable of providing cross-protection against new, unmatched = strains of=20 pathogens such as influenza. Inovio=E2=80=99s proprietary = electroporation-based=20 DNA vaccine delivery technology has been shown by initial human = data to=20 safely and significantly increase gene expression and immune = responses.=20 Inovio=E2=80=99s clinical programs include HPV/cervical cancer = (therapeutic) and=20 HIV vaccines. An IND has been filed for an avian influenza = vaccine.=20 Partners and collaborators include Merck, Tripep,=20 University of Southampton, University of=20 Pennsylvania, and HIV Vaccines Trial Network. = Inovio=E2=80=99s product=20 candidates and technologies are protected by an extensive global=20 intellectual property portfolio. More information is available at = http://cts.businesswire.com/ct/CT?id=3Dsmart= link&url=3Dhttp%3A%2F%2Fwww.inovio.com&esheet=3D6004941&lan=3D= en_US&anchor=3Dwww.inovio.com&index=3D1.=20

This press release contains certain forward-looking = statements=20 relating to our plans to develop electroporation-based drug and = gene=20 delivery technologies and DNA vaccines. Actual events or results = may=20 differ from the expectations set forth herein as a result of a = number of=20 factors, including uncertainties inherent in clinical trials and = product=20 development programs (including, but not limited to, the fact that = pre-clinical and clinical results referenced in this release may = not be=20 indicative of results achievable in other trials or for other = indications=20 and that results from one study may not necessarily be reflected = or=20 supported by the results of other similar studies), the = availability of=20 funding to support continuing research and studies in an effort to = prove=20 safety and efficacy of electroporation technology as a delivery = mechanism=20 or develop viable DNA vaccines, the availability or potential = availability=20 of alternative therapies or treatments for the conditions targeted = by the=20 parties or their collaborators, including alternatives that may be = more=20 efficacious or cost-effective than any therapy or treatment that = the=20 parties and their collaborators hope to develop, evaluation of = potential=20 opportunities, issues involving patents and whether they or = licenses to=20 them will provide the parties with meaningful protection from = others using=20 the covered technologies, whether such proprietary rights are = enforceable=20 or defensible or infringe or allegedly infringe on rights of = others or can=20 withstand claims of invalidity and whether the combined company = can=20 finance or devote other significant resources that may be = necessary to=20 prosecute, protect or defend them, the level of corporate = expenditures,=20 assessments of the companies=E2=80=99 combined technology by = potential corporate=20 or other partners or collaborators, capital market conditions, our = ability=20 to successfully integrate Inovio and VGX = Pharmaceuticals, the=20 impact of government healthcare proposals, our ability to maintain = listing=20 of our common stock under the rules and regulations of the NYSE = Amex and=20 other factors set forth in our Annual Report on Form 10-K for = the=20 year ended December 31, 2008, our Form 10-Q for the three = months=20 ended March 31, 2009, and other regulatory filings = from=20 time to time, including our current report on Form 8-K reporting = the=20 closing of the merger transaction with VGX Pharmaceuticals,=20 Inc. There can be no assurance that any product in = Inovio=E2=80=99s pipeline=20 will be successfully developed or manufactured, that final results = of=20 clinical studies will be supportive of regulatory approvals = required to=20 market licensed products, or that any of the forward-looking = information=20 provided herein will be proven accurate.

Source: Inovio = Biomedical=20 Corporation

Inovio Biomedical
Bernie Hertel, 858-410-3101=20 (Investors)
or
Richardson & Associates
Jeff = Richardson,=20 805-491-8313 (Media)

Home | About Us | Products | Technology | Clinical Trials | News & Events | Investor=20 Relations
=C2=A9 Copyright 2008 Inovio Biomedical = Corporation. All=20 Rights Reserved. | Privacy | Search | Glossary | F= AQs | Site Map | Conta= ct |=20 Safe=20 Harbor